List of Therapeutic Companies in Switzerland - 127

About 4D Lifetec AG 4D Lifetec is a pioneer on a mission to revolutionize early cancer detection. Our easy and powerful blood tests can detect cancer at its earliest stages (I and II), offering you peace of mind and proactive well-being protection. Sophisticated artificial intelligence (AI) enhances our immunological high-throughput blood assays which in turn enables timely intervention and treatment.

AB2 Bio Ltd., located at the Innovation Park of the École Polytechnique Fédérale de Lausanne (EPFL), is a drug discovery and development company focused on developing “best in class” innovative therapies for the treatment of inflammatory diseases with large unmet medical needs. Inflammation is a natural defense mechanism. However, dysregulated and persistent inflammatory processes are the basis of several chronic inflammatory and autoimmune diseases, such as: NLRC4 mutation and XIAP deficiency (primary HLH), Macrophage Activation Syndrome (secondary HLH), Adult onset Still's Disease and others. AB2 Bio is developing drugs that will not only treat the symptoms but also target the underlying causes of inflammation-based diseases. Extensive Phase I, Ib and II clinical trials demonstrated a high tolerance and an excellent safety profile of our drug. We have advanced clinical programs in primary HLH: NLRC4 mutation and XIAP deficiency and in Adult onset Still’s Disease.

Abologix is a biopharmaceutical company based in Geneva, Switzerland. The company is a spin out from the laboratories of Prof. Beat Imhof and Thomas Matthes at the University of Geneva and the Geneva University Hospitals. The company is developing two monoclonal antibodies that selectively block two novel pharmacological targets. Several oncological medical indications are being pursued.

AC Immune SA is a clinical-stage biopharmaceutical company and a global leader in precision prevention for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and NeuroOrphan indications driven by misfolded proteins. The Company’s two clinically validated technology platforms, SupraAntigen® and Morphomer®, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features sixteen therapeutic and diagnostic programs, including five in Phase 2 development and one in Phase 3. AC Immune has a strong track record of securing strategic partnerships with leading global pharmaceutical companies, resulting in substantial non-dilutive funding to advance its proprietary programs and >$4.5 billion in potential milestone payments plus royalties.

ADC Therapeutics is a commercial-stage global pioneer in the field of antibody drug conjugates (ADCs). Our goal is to be a leading ADC company that transforms the lives of those impacted by cancer. To achieve this, we are focused on unlocking the potential value of our robust ADC portfolio across two pillars of growth: hematology and solid tumors. We are a pioneer in the ADC field with specialized end-to-end capabilities unique to ADCs including a validated technology platform, a growing next-generation research & development toolbox and a proven track record that includes an approved and marketed product. We aim to expand our portfolio and accelerate the development of our pipeline through targeted investments and in collaboration with strategic partners. In this way, we plan to pursue multiple targets in parallel, enabling us to prioritize and ensure disciplined capital allocation strategy while advancing the most promising candidates in both hematology and solid tumors. Our CD19-directed ADC ZYNLONTA® (loncastuximab tesirine-lpyl) received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy. Founded in 2011, ADC Therapeutics is based in Lausanne, Switzerland, with operations in London and New Jersey. Our highly skilled global team is committed to confronting cancer with the full potential of our science and transforming the treatment paradigm for patients with cancer. For more information, please visit https://www.adctherapeutics.com/.

Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders. Allosteric modulators offer several potential advantages over conventional non-allosteric molecules and may offer an improved therapeutic approach to conventional "orthosteric" small molecule or biological drugs. Addex's allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention. Addex's lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is poised to start a pivotal registration clinical trial for Parkinson’s disease levodopa induced dyskinesia (PD-LID) in H1 2021. Addex is also investigating dipraglurant's therapeutic use in blepharospasm (a type of dystonia), for which a clinical trial is expected to be initiated in H1 2021. Addex's third clinical program, ADX71149 (mGlu2 positive allosteric modulator or PAM), developed in collaboration with Janssen Pharmaceuticals, Inc., is scheduled to enter a phase 2a proof of concept clinical study for the treatment of epilepsy in H1 2021. Addex’s GABAB PAM program has been licensed to Indivior PLC for the treatment of addiction. Preclinical programs include GABAB PAM for CMT1A, mGlu7 NAM for PTSD, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative disorders. Addex is listed on the SIX Swiss Exchange and NASDAQ Capital Market, and trades under the ticker symbol "ADXN".

ADIENNE is an integrated biopharmaceutical group of companies based in Lugano, Switzerland, with a proprietary portfolio of orphan-designated marketed medicinal product, clinical and preclinical product candidates focusing on critical conditions of high unmet medical needs.

Adoram Therapeutics is an Swiss-based biotech startup focused on developing cutting-edge therapeutic assets. Our pipeline includes two differentiated preclinical-stage allosteric modulators, backed by compelling preclinical proof-of-concept (PoC) data from ex vivo human and in vivo mouse studies. Asset 1 is a negative allosteric modulator of A2AR, a best-in-class immuno-enhancer with excellent potential for immunotherapy in solid tumors. This asset is poised to synergize with existing and emerging blockbuster therapies, including immune checkpoint blockade (ICB) monoclonal antibodies, to offer enhanced efficacy in cancer treatments. Asset 2 is a first-in-class positive allosteric modulator of A2AR, with the potential to transform the treatment of various inflammatory, immunological, and metabolic diseases. This asset has wide-ranging therapeutic applications aimed at improving patient outcomes across multiple disease areas. Our allosteric approach to drug development offers a safer, more targeted, and effective alternative to conventional 'orthosteric' small molecules. At Adoram Therapeutics, we are committed to developing the next generation of small molecule medicines that improve the lives of patients worldwide.

Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at www.alcon.com.

Alentis Therapeutics, the Claudin-1 (CLDN1) company, is a clinical stage biotechnology company that focuses on developing first-in-class breakthrough treatments for CLDN1+ tumors and organ fibrosis. Alentis is pioneering a novel approach to modify and reverse the course of disease progression targeting CLDN1, a previously unexploited target that plays a key role in the pathology of tumors and fibrotic diseases across multiple organs. Alentis is the only company developing potential treatments for solid cancers and fibrosis targeting CLDN1. Alentis’ portfolio of anti-CLDN1 monoclonal antibodies includes a novel class of anti-cancer therapies designed to reprogram the tumor microenvironment (TME). The interplay between cancer cells and their surrounding microenvironment is highly promising for drug development as many cancers use the TME to build barriers that shield against immune system attacks. Alentis’ lead oncology asset, ALE.C04, is the first potential treatment to target CLDN1 in solid tumors. In addition, Alentis’ pipeline includes first-in-class therapies designed to modify and reverse the course of advanced organ fibrosis. ALE.F02, which is currently in Phase 1 clinical trials, is designed to target pathological overexpression of CLDN1 outside of the tight junction to resolve and reverse organ fibrosis and is being investigated for the treatment of fibrotic disease in the kidney, lung, and liver. The company was founded in 2019 based on ground-breaking research in the laboratory of Prof. Thomas Baumert MD at the University of Strasbourg and the French National Institute of Health (Inserm).

AMAL aims to tackle the obstacles for effective anti-cancer therapy by stimulating a patient’s immune system in a unique way. KISIMA®, our unique proprietary protein-based immunisation platform is self-adjuvanting and delivers several antigens in one single vaccine. We focus on the development of viable effective cancer therapies. Our most advanced asset is ATP128, a therapeutic vaccine for the treatment of metastatic colorectal cancers.

AMYRA Biotech AG is a Swiss based, privately held biotech company that develops novel, enzyme-based treatments for celiac disease and non-celiac gluten sensitivity. AMYRA's patented technology could transform the lives of millions of people around the globe and provide a new gold standard for treating gluten related disorders.

A start up based in Switzerland that develops biologics to modulate the functions of cytokines and provide substantial therapeutic benefits to cancer patients.

Araris Biotech AG is pioneering a novel linker technology for antibody-drug conjugates (ADCs.) Our linker platform enables the attachment of any payload to ‘off the shelf’ antibodies without the need of prior antibody engineering.

Arkaïya is pioneering a paradigm shift in microbiome science by spotlighting the often-overlooked kingdom of archaea. Unlike bacteria, archaea play a foundational role in gut health, especially during early life, by regulating pH, detoxifying fermentation byproducts, and supporting mucosal immunity. With a focus on Methanobrevibacter smithii (M. smithii), Arkaïya leads the way in uncovering and addressing archaea deficiencies through innovative precision diagnostics and next-generation probiotics. Their proprietary PCR test marks a breakthrough in detecting previously invisible microbiome imbalances, helping shape a healthier, more resilient gut ecosystem. Arkaïya’s mission is to transform our understanding of gut health by unlocking the hidden potential of archaea.

Artiria Medical is a Swiss neurovascular company that empowers catheters and guidewires, developing cutting-edge technologies to revolutionize the limits of neurointerventional procedures. Their medical device offers navigation in brain arteries and stroke treatment, allowing for the treatment of vascular diseases. The company has secured FDA clearance for their real-time, deflectable guidewire and has received funding to advance stroke treatment technology in Europe and the US.

Asceneuron is a clinical stage biotech company focused on the development of orally bioavailable therapeutics for debilitating neurodegenerative disorders with high unmet medical need. The pipeline reflects our ambition to develop treatments for a wide a range of neurodegenerative diseases including orphan tauopathies, Alzheimer’s and Parkinson’s disease. Asceneuron has two clinical stage small molecule O-GlcNAcase inhibitors in development for the treatment of proteinopathies including Parkinson’s Disease, Alzheimer’s disease and related disorders. Asceneuron is a privately held company financed by a renowned syndicate of investors consisting of Sofinnova Partners, M Ventures, SR One, Johnson & Johnson Innovation – JJDC, Inc. (JJDC) and Kurma Partners. For more information, please visit www.asceneuron.com. Further information: www.asceneuron.com

Founded in 2020, based on 10+ years of research at the Swiss Federal Institute of Technology EPFL Brain Mind Institute and Bertarelli Foundation Gene Therapy Platform, Avrion Therapeutics targets genetically-linked neurodegenerative diseases using precision gene therapy to enable long-term solutions. Avrion has developed a first-in-class precision gene therapy platform to selectively and safely target discrete cells in the brain including neurons and astrocytes. This therapeutic platform is supported by a preclinical discovery engine to identify novel targets to treat neurodegenerative diseases with unmet medical need. Avrions’ first clinical candidate gene therapy product, AVR-001, is preparing to enter IND-enabling studies to treat patients with a form of motor neuron disease (amyotrophic lateral sclerosis - ALS), a fatal neuromuscular disorder.

Baliopharm was acquired by Promethera Biosciences on April 10, 2018. Baliopharm was founded in 2006 as Celonic AG, a service company for the contract development and manufacturing of biopharmaceutical compounds, based on the...

Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in the heart of the life sciences hub of Basel area, Switzerland. We are committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with severe bacterial and fungal infections. We have successfully launched two hospital brands: Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of severe bacterial infections. In addition, we have several preclinical anti-infective assets in our portfolio. Basilea currently has about 150 employees and is listed on the SIX Swiss Exchange (SIX: BSLN). Please visit basilea.com.

Beech Biotech is unlocking novel biology to create breakthrough treatments for preeclampsia and other complications of pregnancy. Each year, preeclampsia causes the deaths of 70,000 mothers, 500,000 babies worldwide. Beyond that, long-term health consequences affect 300 million surviving mothers and their preterm infants. A key unmet need are medicines that treat only the mother without exposing the fetus to additional risk. We are addressing this need by developing “Mother only” monoclonals, achieved by a patented modification that blocks antibodies from crossing the placenta. Our lead asset, MOm303, binds and eliminates maternal sFlt-1, a known cause of vascular breakdown in preeclampsia, and releases placental growth factor, thus restoring the healthy balance of these factors. This has the potential to prolong pregnancy and reduce the consequences of preterm birth

Berlin Heals is a Start-up-Company in Berlin, Germany. We are devoted to the treatment of heart failure. We will redefine heart failure treatment with a novel device that is capable of healing the heart. Contact us at info@berlinheals.de to get in touch with us. Get more Information here: www.berlinheals.de

BioVersys AG is a privately-owned clinical stage Swiss pharmaceutical company focusing on research and development of small molecules acting on novel bacterial targets with applications in antimicrobial resistance (AMR) and targeted microbiome modulation. With the company’s award-winning TRIC technology we can overcome resistance mechanisms, block virulence production and directly affect the pathogenesis of harmful bacteria, towards the identification of new treatment options in the antimicrobial and microbiome fields. By this means, BioVersys addresses the high unmet medical need for new treatments against life-threatening resistant bacterial infections and bacteria-exacerbated chronic inflammatory microbiome disorders. Our most advanced research and development programmes address nosocomial infections of Acinetobacter baumannii (BV100, Phase 2), and tuberculosis (BVL-GSK098, Phase 2) in collaboration with GlaxoSmithKline (GSK) and a consortium of the University of Lille. BioVersys is located in the TechPark in the thriving biotech hub of Basel.

BioXpress Therapeutics SA is a premier provider of high-quality biologic APIs for unmet need indications, such as cancer, inflammation and autoimmunity.

Bright Peak are developing a portfolio of first-in-class and best-in-class cytokines with optimized biological properties for the treatment of cancer and autoimmune diseases. Through a variety of proprietary technology platforms, Bright Peak is uniquely abled to conjugate its cytokines as payloads to antibodies, creating bespoke, novel and proprietary “Bright Peak Immunocytokines”, and to other cytokines as “duokines”. The Bright Peak Immunocytokines allow tissue- and cell-specific targeting of the cytokine payload with the added potential for significantly enhanced efficacy. One of the many advantages of our approach is its "off-the-shelf" feature. Using a pioneering site-specific ADC-like chemical conjugation technology, any therapeutic antibody at any stage of development can be conjugated with Bright Peak’s cytokine payloads of choice, eliminating the current complexities of antibody engineering and cell line development. Bright Peak’s team works with a passion for innovation and bold science. We are an international research-driven organization dedicated to discovering and developing cutting edge therapies that will make a difference in the lives of patients. We aim to create a vibrant and international corporate culture and are currently hiring in our Basel, Switzerland and Southern California locations.

CARBOGEN AMCIS leverages its world-class chemistry skills to provide seamless drug substance, drug products development and commercialization services for leading pharmaceutical and biopharmaceutical companies. We help customers create a better world by becoming the partner of choice thanks to our innovative solutions. We offer an array of integrated and customized services operating in a fully cGMP-compliant infrastructure, including dedicated Highly Potent API facilities and a clean room for Antibody Drug Conjugates. Beyond our services, we also provide high-quality Cholesterol and Vitamin D analogs. CARBOGEN AMCIS is owned by Dishman Carbogen Amcis Limited, (India). Learn more about us: www.carbogen-amcis.com

CDR-Life is a biotherapeutics company developing novel therapies harnessing the power of the immune system. Today’s cancer immunotherapies are powerful but are not tumor targeted, which compromises both efficacy and safety. We are developing a next generation of highly tumor-selective immunotherapies to truly empower the immune system to eradicate malignant cells without the off-tumor-related limitations of current immunotherapies. CDR-Life has developed the unique M-gager® technology to generate MHC-specific antibody-based T cell engagers that target highly tumor-specific intracellular antigens with unparalleled specificity. Our dual-MHC binding molecule format based on antibody fragments has the promise of developing new immunotherapies with high tumor cell killing potency, longer duration of effect, and lower risk of immune-related adverse effects. CDR-Life is advancing a growing portfolio of novel and highly tumor-selective immunotherapies based on the M-gager® technology.

Cellestia Biotech is pioneering innovative therapeutics based on novel modes of action to treat autoimmune diseases and multi-drug resistant cancers. Our clinical stage drug candidate, CB-103, has demonstrated both safety and biological activity in humans. Along with ongoing Phase 2 IITs for multi-drug resistant cancers, CB-103 is also poised to enter a Proof-of-Concept clinical study for graft-versus-host disease (GvHD)

cellvie is the leader in Therapeutic Mitochondria Transplantation (TMT). The team is seeking to bring about a novel treatment modality, leveraging the therapeutic potential of mitochondria, the powerhouses of the cell. Therapeutic Mitochondria Transplantation, an approach for mitochondria augmentation and replacement, was developed by Dr. James McCully at Harvard Medical School. cellvie was founded to take this technology from bench to bed, starting in heart attacks and solid organ transplantation.

With more than 45 years’ experience in the pharmaceutical industry, Swiss-based CERBIOS is specialized in the manufacturing of Generic APIs&HPAPIs alongside with finished formulations based on its own probiotic strain and exclusive CDMO services for HPAPIs, ADCs and recombinant proteins. 𝐏𝐡𝐚𝐫𝐦𝐚 𝐏𝐫𝐨𝐝𝐮𝐜𝐭𝐬 Cerbios portfolio covers a wide range of drug substances including reduced folates such as Calcium Folinate (Leucovorin Calcium), Calcium Levofolinate, Folinic Acid, 5-Methyl-Tetrahydrofolic Acid Calcium Salt, Sodium Folinate, as well as other folates manufactured exclusively for customers. Starting from 1993 Cerbios specialized further in the commercial manufacturing of HPAPIs, with a particular focus on Vitamin D Derivatives, (analogues). Cerbios has also a long standing experience in the probiotics field. For more than 40 years Cerbios produces its finished pharmaceutical drug based on proprietary strain Enterococcus faecium SF68®, for treatment of diarrhea and dysbiosis by antibiotics. Due to the unique characteristics of SF68®, Cerbios recently marketed two new Food Supplements for the management of ACNE & Seborrheic dermatitis and to boost immune response; other new formulations/application are in development phase. 𝐂𝐃𝐌𝐎 Services Cerbios is the ideal partner from clinical to commercial supply of API, HPAPIs, Payloads, ADCs, Proteins and Antibodies. Services offered include Process & Analytical Development, Scale-up and Clinical Supply, Industrial Validation, Commercial Supply, Full CMC Regulatory Support. Within its ADC dedicated division -Proveo (TM)- Cerbios has leveraged the combined experience in Payloads and recombinant proteins to offer an end-to-end solution for Antibody Drug Conjugates (ADCs). 𝐀𝐧𝐢𝐦𝐚𝐥 𝐇𝐞𝐚𝐥𝐭𝐡 Products CERBIOS offers a range of products for animal feed or veterinary application including probiotic feed additives Cernivet® LBC G35, Cernivet® LBC ME5 PET, Cernivet® LBC M10, Cernivet® LBC M20 plus.

Cimeio Therapeutics is an applied gene editing, cellular, and immunotherapy company developing a portfolio of Shielded-Cell & Immunotherapy Pairs for patients with serious and life-threatening diseases. Cimeio’s proprietary technology platform is based on the discovery of protein variants, which when edited into cells allow them to maintain full function while resisting paired immunotherapy depletion. This technology has significant therapeutic potential, which Cimeio is using to develop curative treatments for patients with genetic diseases, hematologic malignancies, and severe autoimmune disorders.

CIS Pharma is an independent pharmaceutical research and development company that was established in 1952. It is based in the Basel Area, Switzerland and focuses on developing next-gen immuno-conjugates, ADCs, and radioligand. The company also specializes in novel contact lens coating technology.

Combioxin SA is clinical-stage biotech company developing innovative anti-virulence drugs to treat severe bacterial infections and combat antibiotics resistance

Our mission: to give patients back more of their own skin to make them well again. CUTISS is a Swiss clinical-stage life sciences company focussed on regenerative medicine, skin tissue engineering, and skin pigmentation. We are developing the first personalized and automated skin tissue therapy offering life-saving and life-changing medical treatments for patients with severe skin injuries. Our lead product denovoSkin promises to take skin surgery to the next level and revolutionize current treatments. It is a bio-engineered and personalized dermo-epidermal human skin graft, currently in Phase 2 clinical trials in Switzerland and the European Union. It has Orphan Drug Designation for the treatment of burns from Swissmedic, EMA, and FDA. CUTISS is also developing the world’s first machine that can automate the entire production process of the personalised skin graft. Our company’s knowledge in skin bio-engineering and biology offers other growth opportunities in regenerative medicine, and also beyond the medical domain. Established in 2017, CUTISS is a spin-off from University of Zurich (UZH) / University Children’s Hospital. We successfully exited the Wyss Zurich accelerator in 2022. Headquartered at the Bio-Technopark in Zurich, CUTISS won the Top 100 Swiss Startup Award 2020, and has raised over CHF 55 million from private investors, family offices and public bodies.

Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds for in-licensing, we conduct clinical development and then select large pharmaceutical commercialization partners for out-licensing to maximize patient access across the globe. Through this specialized business model, Debiopharm can focus on the development of prescription drugs that target unmet medical needs in oncology and bacterial infections. Debiopharm completed the development and has licensed out 2 compounds: - Triptorelin, the active substance of Decapeptyl®/Trelstar®/Pamorelin®/Triptodur® 1, 3 and 6-month formulation and Moapar®/Salcacyl® -Oxaliplatin, the active substance of the branded Eloxatin®/Elplat®/Dacotin®/Dacplat® If your university or biotech start-up has interesting molecules in early-stage research and you’re seeking a competent and committed partner to develop them further, please contact us!

DiNAQOR is a genetic medicine platform company pioneering early-stage drug development and manufacturing to advance promising gene therapies to the clinic. Our patent-protected, industry leading platform is designed to overcome the challenges and limitations of advanced gene therapy development by using proprietary engineered heart tissue technology (EHT), a novel Loco-Regional Perfusion system (LRP) and a fully integrated manufacturing solution. Our company is headquartered in the Greater Zurich Area, Switzerland, with additional presence in Laguna Hills, California and Hamburg, Germany.

Elthera AG is a Swiss biopharmaceutical start-up company bringing together experienced pharma and biotech executives with cutting-edge academic researchers to develop proprietary, first-in-class oncology drugs using a personalized health care approach. Elthera AG is developing antibodies against a novel target whose expression is strongly correlated with an aggressive tumor phenotype and poor prognosis in various types of cancer. By combining targeted therapies with companion diagnostics, Elthera AG is aiming at providing new personalized treatment options for patients with the most aggressive malignancies

endogena’s mission is to discover and develop first-in-class endogenous regenerative medicines to repair and regenerate tissues and organs. our approach has the potential for a medical treatment paradigm change to effectively address unmet medical needs associated with ageing and genetic diseases. endogena therapeutics is implementing state-of-the art innovation in the field of regenerative medicine. our science combines the latest developments in stem cell biology, artificial intelligence and our expertise in small-molecule drug design to develop breakthrough treatments for degenerative diseases. recent breakthroughs in stem cell biology together with technological advances for phenotypic, functional screening have unlocked our ability to harness the potential of adult stem- and precursor cells. our novel drug discovery approach is based on the concept of selective activation of endogenous progenitor cells for controlled tissue repair and regeneration by small molecules.

Endotelix is a privately held Swiss biotech start-up company and a spin-off from the University of Geneva. Endotelix is dedicated to providing fast, sensitive and reliable solutions for Antiphospholipid Syndrome, including diagnostic tests and therapies.

Engimmune is an immunotherapy company utilising cutting-edge methods for the development of T-cell receptor (TCR)-based immunotherapies including T cell therapies and biologics. By applying our unique protein engineering toolbox we have established and continue to develop proprietary high-throughput technology platforms enabling the discovery of highly potent and safe TCR-based cell therapies and biotherapeutics, thus covering the entire TCR discovery value chain. Operating as a platform technology and product development company, our vision is to become a globally leading provider of best-in-class TCR-based therapeutics for the treatment of serious human diseases with high unmet medical need, with a particular focus on oncology. Engimmune is based in a brand new science park in Allschwill, Basel in Switzerland

Looking for a trusted partner in the development of cell lines and manufacturing processes? Look no further. With over 20 years of experience, we specialize in high-yielding (5-14 g/L), GMP-ready, CHO, and HEK293 cell lines for the production of biologics, biosimilars, and gene therapy (AAV, Adenovirus). We have a proven track record of expressing all types of proteins, including bi-specific mAb, Fc-fusions, viral proteins, cytokines, and more. Our team of scientists is ready to support your project from start to finish, including process development, analytical methods, scale-up, tox-batches, and Master Cell Banking. At our company, we pride ourselves on our commitment to quality and customer satisfaction. Contact us today to see how we can help you achieve your goals and be your trusted partner in cell line and process development.

Exogems uses an FDA-approved medical device (Lipogems®) to produce exosomes from the mesenchymal stems cells in fat. They are developing methods for using these exosomes to deliver therapeutics.

FimmCyte is a pre-clinical stage company dedicated to developing non-hormonal treatments for endometriosis using the immune system. Their vision is to accelerate the path towards an endometriosis cure.

FoRx Therapeutics is a recently incorporated privately-held company aiming to develop first-in-class compounds for cancer treatment.

Genkyotex has become a wholly owned subsidiary of Calliditas and have been delisted from the Euronext stock exchanges. Genkyotex's lead product candidate, setanaxib, is a first-in-class NOX inhibitor that targets NOX 1 and NOX 4, which are major drivers of fibrogenesis in multiple organs. In Q4 2021, Calliditas plans to initiate a 52-week, randomized, placebo-controlled, double-blind, trial with an adaptive phase 2b/3 design with setanaxib in 318 patients with primary biliary cholangitis (PBC). As previously announced in August 2021, Calliditas received FDA fast track designation for setanaxib in PBC. Calliditas will also initiate a Phase 2 proof-of-concept study in head and neck cancer in 2021, which will investigate the administration of setanaxib in conjunction with immunotherapy targeting cancer associated fibroblasts (CAFs). Follow @Calliditas Therapeutics for updates on future developments: https://www.linkedin.com/company/calliditas-therapeutics/

GlycoEra is positioned as the leading precision protein degradation company. Bifunctional biologics (G-LyTACs), designed by our novel and proprietary technology bind to disease-causing proteins and transport them to the lysosome using naturally occurring endocytic receptors. The disease-causing proteins are degraded in the lysosome and removed from the body. Unlike intracellular protein degraders, like PROTACs and molecular glues, our technology can access targets that are extracellular and membrane proteins, thereby opening up novel targets and therapeutic areas for intervention.

❌❓ THE CHALLENGE: Glycans hide the tumor in disguise. ➡ Typical cancer-specific Tumor Glycocodes render the tumor invisible to the immune system, they stay ‘cold’. Intelligently, glycans from that Tumor Glycocode are not present on neighbouring healthy tissue, rendering it a perfect target for eradication & potential use as biomarker for patient selection and treatment response. ➡ So far, efforts to break that code for therapeutic benefits have been unsuccessful. One reason for this is the dynamic shape & motion of glycans, and the inability to manufacture them ex vivo. ⭕❗ THE SOLUTION: Conjugated Glycopeptides. Gnubiotics’ proprietary technology conjugates O-glycans with short protein parts - peptides - ex vivo to form novel glycopeptides that are druggable targets amenable to mass production. 🔜 Breaking the Tumor Glycocode. Since 2019, multiple preclinical models have demonstrated proof of concept for the lead compound GNU101 to be orally bioavailable, resisting degradation, and surviving enzyme proteolysis. The preclinical body of evidence has demonstrated proof-of-concept that the GENESIS platform based glycopeptides are able to turn 'cold' into 'hot' tumors, breaking through I/O resistance and inducing tumor cell killing. 💡 THE TEAM: We are a highly specialized team of Founders, Scientists and Entrepreneurs pursuing the transition from a large basis of preclinical evidence into IND-readiness and the clinics with First-in-human clinical phase 1 study for colorectal cancer patients in 2024/2025. 📥 Curious to learn more? Check out our new website and contacts 🌐 https://gnubiotics.com/

Granite Bio is a biotechnology company developing first-in-class antibodies that target the root causes of a variety of inflammatory, autoimmune and fibrotic conditions. Granite is backed by leading healthcare venture firms including Versant Ventures, Novartis Venture Fund, Forbion and Sanofi Ventures.

HAYA Therapeutics is a precision medicines company developing RNA-guided programmable therapeutics targeting the regulatory genome for serious health conditions including cardiovascular disease and cancer. The company is using its innovative cell-state modifying platform to gain novel insights into the biology of long non-coding RNAs (lncRNAs), the ‘dark genomes’ information processing features and ‘source code’. HAYA’s lead therapeutic candidate is HTX-001, an antisense oligonucleotide targeting Wisper, which is a tissue and cell-specific cardiac lncRNA known to play a role in heart failure. The company is also developing a pipeline of lncRNA-targeting candidates for the cell-specific treatment of diseases in other tissues, including the lungs and the microenvironment of solid tumor cancers. Headquartered at the life sciences park Biopôle in Lausanne, Switzerland with laboratory facilities at JLABS @ San Diego, HAYA is led by a world-class team of experts in programmable and precision RNA-targeted therapeutics and is supported by a strong investor consortium. HAYA’s mission is to identify and develop breakthrough disease-modifying therapeutics with the potential for greater efficacy, safety, and accessibility than existing treatments.

Helsinn is a global pharmaceutical company that builds, launches, and commercializes products to improve the quality of life for patients with cancer and chronic disease, with a focus on supportive care, oncology, and dermato-oncology. Founded in 1976, Helsinn has over 40 years of experience in the pharmaceutical industry, with an extensive network of long-standing trusted partners enabling a commercial presence in 190 countries. Helsinn Healthcare SA, headquartered in Lugano (Switzerland), oversees the activities of the three Helsinn Group’s subsidiaries (Helsinn Birex Pharmaceuticals Ltd., Helsinn Therapeutics (U.S.), Inc., Helsinn Pharmaceuticals (Beijing) Co., Ltd.), defining and implementing the Group’s strategy. Our mission is to champion and support patients with cancer and chronic diseases at every stage of their journey, by providing them with the best medications and solutions based on their needs and preferences. Follow our LinkedIn page to stay updated with news from Helsinn Group! If you are interested in joining us, please visit our website (www.helsinn.com): applications should only be submitted via the appropriate country portal, available under “Careers – Join us” website section. * This account shall only be used to share news concerning Helsinn. We would like to emphasize that due to the highly regulated nature of the pharma industry, we cannot engage with you online in any discussions concerning our or other companies’ products and/or services, and/or treatment options. It is best to hold such discussions and to seek guidance privately from your healthcare professional.

HemostOD is a biotech company based at the EPFL Innovation Park in Lausanne, Switzerland. They are a preclinical stage company developing a therapeutic platform inspired by platelet biology.

We are a start-up medical device company originating from ETH Zurich and are passionate about developing life saving therapies. Our mission is to develop a breakthrough medical device for the most urgent healthcare issues. Focusing on patients’ needs, we translate the most promising research to the clinics and ensure patient access to scientific progress as soon as possible. As pioneers we take courageous decisions and are shaping the future of medicine. We first focus on finding an efficient therapy for patients with sepsis, a devastating condition causing millions of deaths annually.

Histide™ is pioneering Recoding Therapeutics™, a novel therapy using non-mutagenic extracellular technologies to direct cell fate. Based on the universal understanding of the mechanisms underlying mammalian cell behavior, Histide™ has created an innovative platform of complex microenvironments with the capacity to dictate the precise commitment of various cell types. These include cells from different tissue origins and at contrasted differentiation stages, ranging from stem cells to specialized mature cells. In contrast to previously developed gene therapies or RNA based therapies, the Histide™ technology has the major advantage of not requiring the introduction of foreign molecules inside the cell which in turn may be irreversibly harmful to its functioning. Recoding Therapeutics™ are instead an extracellular technological approach that promotes and stimulates the cell’s natural capacities to redirect its own fate by integrating accurate micro-environmental recoding signals. This allows for a precise and fine functional tuning that offers a master control over the cell biology. Recoding Therapeutics™ are the closest to the natural cell physiology, hence, providing significantly improved safety and efficacy. They have the potential to address a wide range of altered cell conditions and diseases through the regeneration of a large majority of the human body tissues. Histide™ has created a broad and disruptive intellectual property portfolio including Recoding Molecules™, Micro-environmental Design and Therapeutical Development being a technological break-through with vast indication spectra of pharmaceuticals, medical devices and medical cosmetics. Based in Europe, Histide™ has developed strong international collaborations with leading Universities and Institutes around the globe in order to make its expertise and technology known and promote the Recoding Therapeutics™.

At Immitra Bio, we are pioneering a next-generation gene therapy platform, harnessing Hematopoietic Stem Cells and their downstream cell lineages, such as red blood cells as living, in-vivo biotherapeutic protein factories. The CRISPR-Cas-based cell and gene therapy platform we are developing is versatile and promises to be easily reprogrammable.

ImmunOs Therapeutics AG is developing the next generation of immunotherapies that have a role in the innate immune system for cancer and autoimmune diseases. The company is developing therapies that not only have direct anti-tumor effects but also remodel the tumor microenvironment to enhance the efficacy of existing immunotherapies. This portfolio of next generation, novel immunomodulatory proteins target diverse and key immunoregulatory receptors. Our lead program iosH2, now advancing to Phase 1 studies, is a multi-functional fusion protein that blocks specific LILRB (leukocyte immunoglobulin-like) receptors and thereby activates anti-tumor responses in multiple cancers with monotherapy and in combination with checkpoint inhibitors (CTLA-4, PD-1, PD-L1, CD47) and costimulatory agonists (e.g. 4-1BB).

We are a Swiss-based early-clinical stage biotech start-up. Using our breakthrough technology, ACINDA, we develop first-in-class, protein-protein interaction antagonists against invasive cancers.  Invasight's precise therapies will make a positive difference in the lives of patients with invasive cancers. 

iOnctura is a clinical-stage biotech developing selective cancer therapies against targets that play critical roles in multiple tumor survival pathways such as cellular proliferation; escape from immune detection; and drug resistance. iOnctura’s pioneering approach to drug development is expected to offer significant clinical benefits over the traditional approach of targeting a single pathway alone. iOnctura has progressed two therapeutic candidates into mid-stage clinical development: IOA-244, a highly selective allosteric inhibitor of PI3Kδ to treat Treg-driven tumors; and IOA-289, a highly selective, non-competitive autotaxin (ATX) inhibitor to treat cancer associated fibroblast (CAF) driven tumors. iOnctura is backed by specialist institutional investors including M Ventures, Inkef Capital, VI Partners, Schroders Capital, and 3B Future Health Fund.

iQone Healthcare Switzerland is an independent Swiss specialty pharma company focussing on the commercialisation of biosimilars, orphan drugs and oncology products. As a Swiss company founded by leading members of the pharmaceutical industry, we have created an agile model to accelerate the transition to biosimilars. Today, the choice of biosimilars is tangible proof of physicians' commitment to the public interest. And prescribing the best available treatment at the best price is an issue of social responsibility. Be the actor of this paradigm shift together with us!

Legacy Healthcare is a Swiss-based biopharmaceutical company focused on leveraging the pleiotropic activity and strong safety profile of plants to develop prescription botanical drugs that address serious medical conditions. Our first product candidate, CINAINU, has demonstrated strong safety and efficacy in patients suffering from alopecia areata, a chronic autoimmune condition with highly damaging psycho-social issues that impact all who suffer from it, especially children.

Leman Biotech Co., Ltd. is a spin-off of EPFL co-founded by Prof. Li Tang (Head of Laboratory of Biomaterials for Immunoengineering). Leman Biotech aims at developing and commercializing new metabolic cancer immunotherapies. Recently, the start-up company closed a US$11 million angel financing round. The money raised will enable it to accelerate the preclinical studies of biomolecule and cell based therapies and prepare for entering clinical trials. The headquarter of the company is now in Shenzhen, a highly vibrant city with the highest number of start-ups per head of population in China. Currently, Leman Biotech is launching a new drug discovery center in Lausanne, Switzerland, to initiate clinical trials in Europe.

NovImmune has successfully divested EmaCo AG, a newly established company owning emapalumab and related assets to Sobi on 18 July 2019. NovImmune SA will continue to operate and focus on its bispecific technology and associated programs and will rebrand as: “Light Chain Bioscience – A brand of Novimmune SA”. The brand Light Chain Bioscience brings to life the research and development of novel multi-specific antibodies that rely on their light chain for their function. A key distinctive feature of these multispecific antibodies is their native human structure, making them well tolerated and easy to develop. Thus far, NovImmune has advanced seven drug candidates to treat a range of conditions. The Company’s pipeline is a balance of preclinical and clinical candidates for validated and novel targets. NovImmune has established a next-generation antibody drug discovery platform that includes novel bispecific antibody drug capabilities - the simple, stable and smart kappa-lambda-body™. In 2009, NovImmune received the European Biotechnica Award. In 2010, NovImmune entered a partnership with Genentech to advance the Company’s anti-IL17 drug candidate. In addition to pursuing additional drug discovery, development and commercialization partnerships, the Company plans to bring selected drugs to market for focused applications.

LimmaTech Biologics AG is a Swiss-based clinical stage biopharmaceutical company. We are advancing our proprietary vaccine pipeline to halt the increasing threat of global infections due to emerging antibiotic resistance (AMR) and sexually transmitted diseases. In addition to our proprietary research, we also develop vaccines together with GSK.

Linkster is a swiss-based precision medicine company focusing on multi-specific antibodies and tissue-specific delivery. The company creates next generation targeted therapeutics through its Flycode® platform for high-throughput cellular and in vivo antibody engineering. Linkster has entered into several agreements with pharmaceutical and biotech companies and is actively seeking further partnerships for the co-development of innovative therapeutic products.

Lunaphore Technologies S.A., a Bio-Techne brand, is a Swiss-based life sciences company founded in 2014 with the vision of enabling spatial biology in every laboratory. Lunaphore has developed a game-changing chip technology which can extract spatial proteomic and genomic data from tumors and transform any simple assay into multiplex spatial biology without complexity. Lunaphore empowers researchers to push the boundaries of research to ultimately develop the next generation personalized therapies.

Mabylon AG is a Swiss biotechnology company harnessing the therapeutic potential of naturally occurring human antibodies to treat allergies, neurodegenerative diseases, and inflammation. The firm’s strength is rooted in extensive and successful experiences in both the pharmaceutical and biotech industry, along with a solid academic track record.

MMV is a leading product development partnership (PDP) in the field of antimalarial drug research and development. Our vision is a world in which innovative medicines will cure and protect the vulnerable and under-served populations at risk of malaria, and ultimately help to eradicate this terrible disease. Our success in research and access & product management comes from our extensive partnership network of over 375 pharmaceutical, academic and endemic-country partners in 50 countries. www.mmv.org www.facebook.com/medicinesformalaria www.twitter.com/medsformalaria www.youtube.com/user/MMVmeds4malaria http://plus.google.com/+mmvorgmedsformalaria

Memo Therapeutics AG (“MTx”) is a late-stage biotech company translating unique human immune responses into superior medicines through the development of best-in-class antibodies to treat viral infections and cancer. The Company’s lead program, Potravitug, is in Phase II development targeting BK viremia (BKV) in kidney transplant recipients, an infection which can result in decreased kidney functionality and longevity and reduced patient survival. Potravitug has the potential to become the best and first-in-class BKV disease-modifying therapy for kidney transplant patients. Alongside Potravitug, MTx is focused on discovering novel antibody-target pairs for oncology based on tumor infiltrating B-cells derived leveraging tertiary lymphoid structure biology. The Company has a partnership in place with Ono Pharmaceutical for two oncology targets. Underpinning MTx’s core assets is its proprietary DROPZYLLA® technology, an antibody repertoire copying engine with high-throughput screening capabilities. MTx is a private company located in Schlieren / Zurich and backed by investors including Ysios Capital, Kurma Partners, Pureos Bioventures, Swisscanto, Vesalius Biocapital and Adjuvant Capital.

MimiX biotherapeutics introduces Sound Induced Morphogenesis. We extend the boundaries of biofabrication, making bioengineered, artificial human organs and tissues a future reality. Sound Induced Morphogenesis (SIM) is a revolutionary approach in biofabrication. It mirrors nature’s design, to aggregate and pattern biologicals by tuning sound profiles under contactless, fast and delicate culture conditions resulting in a morphologically induced tissue generation. We introduce cymatiX®, a unique acoustic biofabrication solution that makes the Sound Induced Morphogenesis technology easily accessible to the scientific and clinical community Visit www.mimixbio.com to learn more. mimiX biotherapeutics is a Swiss biomedical company.

Molecular Partners AG operates as a clinical-stage biopharmaceutical company. It is developing Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of wet age-related macular degeneration, as well as for diabetic macular edema; and MP0250 that binds and inhibit vascular endothelial growth factor and hepatocyte growth factor pathways, which restores clinical sensitivity to various standard-of-care therapies in multiple myeloma. The company is also developing MP0274 that is in Phase I clinical trials for HER2-positive solid tumors; MP0310, which is in Phase I clinical trials for immuno-oncology; MPO317, a tumor-localized immune agonist that activates immune cells in the tumor; and Peptide-MHC, a tumor-localized immune-cell agonist to attack tumors. It has strategic partnerships with Allergan, Inc. and Amgen SA; and collaboration with AGC Biologics to develop anti-COVID-19 DARPin program. Molecular Partners AG was founded in 2004 and is headquartered in Schlieren, Switzerland.

MoonLake has a portfolio of therapeutic programs based on the phase 3-ready Nanobody® Sonelokimab (SLK, M1095/ALX-0761), a biologic molecule potentially capable of driving disease modification in dermatology and rheumatology patients. A single-domain antibody (sdAb), also known as a Nanobody®, is an antibody fragment consisting of a single monomeric variable antibody domain. Like antibodies, Nanobodies® are able to bind selectively to a specific antigen with high affinity.

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or axial spondyloarthritis. MoonLake Immunotherapeutics was incorporated in 2021 and is headquartered in Zug, Switzerland.

MPC Therapeutics is a biotechnology company focused on cellular rejuvenation to fight cancer & degenerative pathologies. They develop a class of compounds with applications in immunotherapy and metabolic diseases. The company is founded on the belief that they can manipulate cell behavior to fight cancer and degenerative diseases.

MUVON Therapeutics is a clinical stage Life Science spin-off from the University of Zurich developing a therapeutic platform for the regeneration of skeletal muscle tissue based on autologous cells, not only repairing damaged tissue but also increasing the regenerative potential of weakened muscles. Our initial area of focus is the treatment of stress urinary incontinence in women, supporting them respectfully throughout their journey to a healthy life.

Spin-off from the Institute for Research in Biomedicine (IRB) in Bellinzona, Switzerland, aimed at shaping the intestinal microbiota for the cure and prevention of diseases such as bowel diseases and cancer. The gut ecosystem conditions the function of all our organs and plays a fundamental role in our wellbeing. The mucosal immune system has co-evolved with the intestinal microbiota to adapt its function to a number of environmental and possibly pathogenic factors. MV Bio leverages a microbiota-mediated mechanism regulating the physiological response of the intestinal immune system to amplify secretory IgA antibodies in dysbiotic conditions and in vaccination protocols. The lead indications of the patent protected ApyraMed® platform are treatments for Inflammatory Bowel Disease (IBD), enhancement of the tumoricidal response in cancer immunotherapy by selectively adapting the intestinal microbiota function to the activity of checkpoint inhibitors and the protection from antibiotic induced dysbiosis, thereby safeguarding our organism from opportunistic infections (e.g. by Clostridioides difficile and pathogenic Escherichia coli) that take advantage from the destruction of the intestinal resistance to colonization by enteropathogens.

Mymetics Corporation (OTCQB: MYMX) is a Swiss based biotechnology company, with a Research Lab in the Netherlands, focused on the development of next-generation preventative vaccines for infectious diseases. It has currently has 5 vaccines in its pipeline: HIV-1/AIDS, intra-nasal Influenza, Malaria, Herpes Simplex Virus and the RSV vaccine. Mymetics’ core technology and expertise are in the use of virosomes, lipid-based carriers containing functional fusion viral proteins and natural membrane proteins, in combination with rationally designed antigens. The company’s vaccines are designed to induce protection against early transmission and infection, focusing on the mucosal immune response as a first-line defense, which, for some pathogens, may be essential for the development of an effective prophylactic vaccine. The company’s unique approach is being validated through partnerships with leading pharmaceutical or research organizations, including Astellas Pharma, PATH-MVI and the Bill and Melinda Gates Foundation. Mymetics is registered in the US and trades on the OTCQB venture stage marketplace.

Neovii is a global leader in polyclonal antibody immunosuppressive therapy used in organ transplantation and hematology/oncology. Our lead product, Grafalon®, has been used for over 30 years to treat patients and is available in more than 40 countries world wide. It has approval for use in immunosuppressive therapies for prevention of graft- versus- host disease in stem cell transplantation, prevention and treatment of rejection in solid organ transplantation and in treatment of aplastic anemia.

Nerai Bio is a biotech startup pioneering ultra-specific genome editing technologies to treat genetic diseases. Using their AI-driven MORPHEME platform, they engineer novel gene-editing proteins that can precisely target and correct DNA at any location, addressing a broader range of genetic mutations than existing tools like CRISPR. Their lead therapeutic candidates focus on severe liver disorders, aiming to provide a single, permanent cure for conditions currently treated with lifelong care. Recently, Nerai Bio secured CHF 150,000 from Venture Kick to advance business development, preclinical validation studies, and partnerships.

Neurimmune is a biopharmaceutical company translating human immune memory into antibody therapeutics. Neurimmune discovered aducanumab for Alzheimer's disease together with a team of researchers at the University of Zurich and licensed it to Biogen. Neurimmune's Reverse Translational Medicine technology platform translates the genetic information from human white blood cells into selective high-affinity antibody drug candidates. Besides aducanumab, Neurimmune discovered cinpanemab for Parkinson's disease, the anti-tau antibody BIIB076 for Alzheimer's disease, the anti-miSOD1 antibody AP-101 for amyotrophic lateral sclerosis, and the anti-ATTR antibody NI006 for cardiomyopathy. These programs are currently evaluated in clinical trials.

Neurosterix is a biopharmaceutical company focused on developing allosteric modulators for the treatment of neurological disorders. Our drug discovery and development platform identifies and develops allosteric modulators — molecules that increase or decrease the activity of target receptors by binding outside of the “active site” where endogenous ligands and traditional drugs operate. Through this platform, Neurosterix’s novel drug candidates have the potential to provide medicines with improved efficacy, safety and tolerability for patient communities suffering from underserved neurological disorders.

Based in Lausanne, Switzerland, NewBiologix SA is a technology innovation company developing a proprietary and breakthrough DNA integration platform for the advanced engineering of human and mammalian cell lines for the improved production of viral vectors used in gene therapies.

MISSION & VALUES To serve our patients we design affordable, safe and effective therapeutics to safeguard and empower the brain throughout all stages of life. We value partnership and Integrity, we are ethical and responsible and show respect and compassion for our patients. R&D STRATEGY The successful companies of tomorrow are those that go beyond delivering products to delivering real solutions and services. R&D is the cornerstone of our company and we promote ingenuity through an effective intellectual property policy. The advancements in science mean that more targeted, more (cost-)effective treatments are within reach and we are here to take on this challenge. Our innovative R&D is centered on patients’ needs and delivering affordable, safe and effective solutions. Not only will these enable us to improve access to quality healthcare and meet unmet needs, but they will also deliver the sustainable growth required to allow us to continue to invest in innovative research & development. FOCUS Partner in the field of psychiatry and neurology in attentionnal and cognitive enhancement and neurological therapies in particular. These disorders remain largely underdiagnosed and current therapies lack in safety and effectiveness: Attentional Disorders (ADHD, awakening disorders, deficit of alertness) Excessive Daytime Sleepiness (Narcolepsy, Hypersomnias) Pervasive Developmental Disorders (ASD) Cognitive Impairments (MCI, AD) Synucleopathies (PD, LB)

Noema Pharma is a clinical-stage biotech company targeting debilitating central nervous system (CNS) indications. They are committed to developing treatments for debilitating disorders of the central nervous system.

Nouscom is a private clinical stage immuno-oncology company developing off-the-shelf and personalized cancer immunotherapies using proprietary viral vectors with demonstrated high immunogenicity in patients. Nouscom’s clinical pipeline includes NOUS-209, an off-the-shelf cancer immunotherapy assessing the efficacy of the treatment in advanced MSI-H CRC patients in combination with pembrolizumab in randomized phase 2 trials. A Phase 1b study of NOUS-209 monotherapy in Lynch Syndrome Carriers with potential to ‘intercept cancer’ before it occurs is running in collaboration with the National Cancer Institute. Nouscom's second clinical program is NOUS-PEV, a personalized cancer immunotherapy for the treatment of advanced cancers with great unmet medical need. Nouscom has exclusively out-licensed VAC-85135, an off-the-shelf immunotherapy, to Janssen Oncology. The program is under evaluation in a Phase 1 trial for the treatment of Myeloproliferative Neoplasms. Nouscom was founded in 2015 and is headquartered in Basel, Switzerland with operations in Rome, Italy. The company is backed by international life sciences investors: 5AM, Andera Partners, Bpifrance, EQT Life Sciences, Indaco Venture Partners, M Ventures, Panakes Partners, Revelation Partners, Versant Ventures, and XGen Ventures and has raised a total of $130M to date. For more information on Nouscom, please visit the company’s website at www.nouscom.com

NovaGo’s fully human monoclonal antibodies have the potential to become a safe and effective treatment in central nervous system indications. NovaGo’s proprietary antibodies block the function of Nogo-A, one of the most potent and well-studied vascular and nerve growth inhibitors.

Novaremed AG is a clinical-stage Swiss biopharmaceutical company, HQ in Basel, Switzerland, with a subsidiary in Israel. Novaremed is developing an orally active, first-in-class, small molecule (NRD.E1), with a novel mechanism of action, to treat Diabetic Neuropathic Pain.

Novartis is reimagining medicine to improve and extend people’s lives. We deliver high-value medicines that alleviate society’s greatest disease burdens through technology leadership in R&D and novel access approaches. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. About 106,000 people of more than 140 nationalities work together to bring Novartis products to nearly 800 million people around the world.

Novigenix is a Swiss precision medicine company specialized in ImmunoTranscriptomic solutions for early detection of disease, development of novel therapeutics, and drug target discovery. The Novigenix proprietary LITOSeek™ platform is an AI-enabled RNA analytic platform optimized for mapping the response of the immune system to onset and progression of disease. Our analytical pipelines integrate patient multi-omics data with advanced Machine Learning and artificial intelligence approaches to provide actionable insights and precision solutions. Our liquid biopsy products and services include a suite of biopharma solutions for clinical development of novel therapies, drug target discovery, and early detection of Colorectal Cancer. Novigenix provides services to Pharma and Biotech customers by leveraging the proprietary LITOSeek™ data analytics and patient clinical data platform to deliver previously unknown insights into heterogeneity of patient response and development of actionable biomarkers for optimization of new therapeutic modalities. Specialties Precision Medicine solutions in oncology and immunology, ImmunoTranscriptomics, Machine Learning and Artificial Intelligence, clinical development of multi-omics biomarkers, standardized RNAseq platform and analytic pipelines, product development for In-vitro Diagnostics and Liquid Biopsy solutions.

We are a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of our innovative therapy, Tumor Treating Fields. Our commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma and in the U.S. for the treatment of adult patients with malignant pleural mesothelioma. We have ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer and gastric cancer. Headquartered in Switzerland, Novocure has U.S. operations in Portsmouth, New Hampshire and Chesterbrook, Pennsylvania. Additionally, Novocure has offices in Canada, Germany, Japan, Poland and Israel.

Nuclidium is setting a new standard in the precision oncology landscape by developing best-in-class copper-based radiopharmaceuticals that enable the highest accuracy and accessibility for targeted cancer treatment and diagnosis. Our flexible CuTraceTM platform combines copper radiometals with a variety of highly specific cancer-targeting molecules to rapidly develop novel therapeutic and diagnostic programs. The resulting product portfolio leverages the unique properties of copper to achieve an improved safety and efficacy profile with advantageous economics for hospitals and patients. Nuclidium's differentiated "diagnostic to therapeutic" approach de-risks our development pathway. With innovation as our core, we overcome supply limitations in manufacturing and distribution, bringing greater flexibility to medical facilities. We are a diverse and interdisciplinary team focused on changing precision radio-oncology for the better to deliver a true benefit to cancer patients.

Numab Therapeutics is an oncology-focused biopharmaceutical company based in the Zurich-area, Switzerland. At Numab, we are writing the next chapter in cancer immunotherapy by creating multi-specific antibodies that enable the pursuit of novel therapeutic strategies. With our proprietary MATCH™ technology platform we are fueling a new wave of multi-specific drug candidates engineered with versatility and developability in mind. Our lead product was designed to balance potent anti-tumor immunity with a desirable safety profile by targeting 4-1BB, PD-L1 and Human Serum Albumin simultaneously. We believe meeting the highest quality standards in every step of the drug design process matters and will result in better patient outcomes.

Innovating Women’s Reproductive Health and Pregnancy Therapeutics ObsEva is a clinical-stage biopharmaceutical company focused on the clinical development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor and improving ART outcomes.

Headquartered in Lachen, Switzerland, Octapharma is one of the largest human protein manufacturers in the world, developing and producing human proteins from human plasma and human cell lines. Octapharma employs nearly 12,000 people worldwide to support the treatment of patients in 118 countries with products across three therapeutic areas: Immunotherapy, Haematology and Critical Care. Octapharma has seven R&D sites and five state-of-the-art manufacturing facilities in Austria, France, Germany and Sweden, and operates more than 195 plasma donation centres across Europe and the US. Octapharma has 40 years of experience in patient care. Check our community guidelines: https://bit.ly/3M8ioml

Oculis is a global biopharmaceutical company (Nasdaq: OCS; XICE: OCS) purposefully driven to save sight and improve eye care. Oculis’ highly differentiated pipeline comprises multiple innovative product candidates in development. It includes OCS-01, a topical eye drop candidate for diabetic macular edema (DME) and for the treatment of inflammation and pain following cataract surgery; OCS-02 (licaminlimab), a topical biologic anti-TNFα eye drop candidate for dry eye disease (DED) and for non-infectious anterior uveitis; and OCS-05, a neuroprotective candidate for acute optic neuritis (AON). Headquartered in Switzerland and with operations in the U.S. and Iceland, Oculis’ goal is to improve the health and quality of life of patients worldwide. The company is led by an experienced management team with a successful track record and is supported by leading international healthcare investors. For more information, please visit: www.oculis.com

Oncobit is a medtech UZH Spin-off, enabling personalized cancer care by matching patients to the best cancer treatment available. We are developing cancer-specific genomic fingerprinting and personalized monitoring tests and provide therapy decision support.

Onena Medicines is a biopharmaceutical company with a pipeline of first-in-class antibody medicines to treat recurrent and metastatic cancers and selected rare diseases. Onena’s drugs neutralize a new class of secreted ancient growth factors, conserved across species, called Dual SMAD Inhibiting Proteins (DSIPs), that program cancer cells to grow and resist chemotherapy. Blocking DSIPs, as demonstrated in-vivo by Onena, simultaneously reactivates physiological TGF-β and BMP signaling and elicits cellular reprogramming, resulting in cancer cells accepting environmental cell death signals from BMPs and Activins. Onena has developed a proprietary AI-centric antibody drug discovery platform that rapidly generates anti-DSIP neutralizing antibodies, even when no crystal structure of the antigen is available. OMED-101, Onena’s anti-LEFTY1/2 lead candidate antibody, has demonstrated broad efficacy against breast, colorectal and brain cancers without observable toxicities in preclinical models. Through its unique platform, Onena Medicines has discovered several DSIPs and aims to advance multiple neutralizing DSIP antibody drugs into clinical development in the next three years.

Orbis Medicines, a leader in oral macrocycle drug discovery, today announces its launch with a €26 million financing led by global life sciences investor Novo. The company is focused on macrocycle drugs, described as a family of compounds with a platform to discover, develop.

Perseo pharma takes its name from Perseus, the hero of Greek mythology who, by wearing the Cap of Invisibility, was able to slay the Gorgon Medusa whose gaze was turning onlookers into stone. Perseo pharma's therapeutic enzymes, with their stealth coating, are able to invisibly reach their targets so as to slay the disease.

PharmaBiome is a privately-held spin-off company of ETH Zurich and a pioneer in the production of live biotherapeutic products to address disturbances of the gut microbiome. It has developed the first-in-the-industry, patent-protected technology platform for the production of standardized microbiome-based products. Founded in Zurich in 2015, at the intersection of microbiology, biotechnology, and data science, PharmaBiome believes that the future of microbiome-based therapeutics lies in developing the biotechnology needed to produce a solution compatible with the safety, efficiency, and trial requirements of any human medicine. This holds the promise of becoming a first step into the creation of personalized treatments for patients with chronic inflammatory diseases, immune conditions, and special nutritional needs. PharmaBiome has invested years in developing a biology-based analysis tool that allows for the identification and selection of the metabolic functions needed to restore the gut microbiome to a balanced state. The resulting formulation compounds the over 500 different strains that every person hosts to a minimal consortium of bacteria representing a healthy microbiome. The co-culture of this bacterial mix transforms it into a live biotherapeutic product whose active principle is based on the composition, function, and interactions between the microorganisms. The flexibility and speed of this process are a unique advantage to bring to life effective treatment options. Over the years, it has been recognized with several start-up awards such as Venture Kick, the ETH Spark Award, and the BaseLaunch Accelerator.

Polyphor is a Swiss biopharmaceutical company leading the research and development of a new mechanism of action in solid tumors, CXCR4 inhibition, for combination treatment in oncology, using Balixafortide, an innovative molecule based on our inhouse macrocycle chemistry.Polyphor has also discovered and is developing the OMPTA (Outer Membrane Protein Targeting Antibiotics). The OMPTA are potentially the first new class of antibiotics against Gram-negative bacteria.

PreCombTherapeutics AG is a privately held Swiss biotechcompany focused on in vitro cancer diagnostic to improve cancer management. It's automated microtumor-based 3DTwin™ technology enables clinical institutions to integrate the technology on-site in the hospital. The test makes it possible to functionally evaluate multiple cancer drugs, drug combinations and drug concentrations directly on patient-derived micro-tumors to maximize treatment outcome.

Proteomedix enables personalized medicine by developing non-invasive diagnostic tests to detect and assess the prognosis of cancer, as well as to match patients with safer and more effective therapies. The first product is a blood-based test for the early diagnosis of prostate cancer. The main benefit of this test is a significantly higher accuracy compared to today's clinical standard (blood-based PSA test). This reduces unnecessary biopsies and thus results in significant cost savings for the healthcare system and less discomfort for the patient.

Pulmonx has developed the Zephyr Endobronchial Valve, a minimally invasive treatment for COPD/emphysema. The one-time procedure is done by bronchoscopy and requires no cutting or incisions. During the procedure, on average 4 tiny valves are placed in the airways to block off the diseased parts of the lung which allows trapped air to escape until the lobe is reduced. Reducing hyperinflation allows the healthier parts of the lungs to expand and take in more air. This results in patients being able to breathe easier and have less shortness of breath.1 Complications of the Zephyr Endobronchial Valve treatment can include but are not limited to pneumothorax, worsening of COPD symptoms, hemoptysis, pneumonia, dyspnea and, in rare cases, death.1 1. Criner G et al AM J Resp Crit Care Med 2018, Published on 22-May-2018 as 10.1164/rccm.201803-0590OC Brief Statement: The Pulmonx Zephyr® Endobronchial Valves are implantable bronchial valves indicated for the bronchoscopic treatment of adult patients with hyperinflation associated with severe emphysema in regions of the lung that have little to no collateral ventilation. The Zephyr Valve is contraindicated for: Patients for whom bronchoscopic procedures are contraindicated; those with evidence of active pulmonary infection; known allergies to Nitinol (nickel-titanium) or its constituent metals (nickel or titanium); known allergies to silicone, or with large bullae encompassing greater than 30% of either lung; Patients who have not quit smoking. The Zephyr Valve should be used with caution and only after careful consideration in treating patients with: Prior lung transplant, LVRS, median sternotomy, or lobectomy; Congestive heart failure or recent myocardial infarction; FEV1 <15% of predicted value. Use is restricted to a trained physician. Prior to use, please reference the Zephyr Endobronchial Valve System Instructions for more information on indications, contraindications, warnings, all precautions, and adverse events.

Quadira Biosciences combines two outstanding cutting-edge technology platforms to complete the development and preclinical studies of ten new Antibody Drug Conjugates (ADCs) within 4 months each. This dramatically extend the previously rather limited commercial lifecycle of antibody drugs. Collectively, the planned ADC portfolio has a market value of $25 billion. The first new anti-HER-2 ADC has already been completed and documented in the last four months and is currently being prepared for licensing.

Quercis Pharma AG is leveraging its novel antithrombotic platform to deliver safe and innovative treatments to patients with a variety of complex diseases that are poorly addressed by today’s medicines and is committed to providing affordable access to these potentially life-saving therapies

Redbiotec is a privately held Swiss biopharmaceutical company, based in Zurich-Schlieren. Founded in 2006 as a spin-off of the Swiss Federal Institute of Technology in Zurich (ETH Zurich), the company has won several awards, including the renowned W.A. De Vigier Award. The company is successful in producing key proteins and genetic materials for biopharma and food industry thanks to a dedicated scientific team with expertise in multiple disciplines from immunology and microbial engineering to protein engineering. Presently, Redbiotec is involved in the alternative-dairy development. We are using precise fermentation in different expression platforms to recombinantly produce milk proteins, such as caseins, with high yield and their post-translational modifications. We actively evaluate partnering opportunities with the goal of reinforcing our portfolio, and/or to add value to the process developed by our collaboration partners. We welcome strategic partnerships to use our recombinant proteins for animal-free food products and to increase the impact of our technology platforms.

Release Therapeutics is a preclinical-stage BioMedTech company developing the first cell macroencapsulation technology designed to deliver potent therapeutic proteins beyond the human blood-brain barrier.

Relief Therapeutics Holding AG, a biopharmaceutical company, provides patients with therapeutic relief from serious diseases with high unmet medical need in Switzerland, rest of Europe, North America, and internationally. The company focuses on clinical-stage programs based on molecules with a history of clinical use and either initial human activity or efficacy data or a strong scientific rationale. Its lead compound is RLF-100 (aviptadil), a synthetic human vasoactive intestinal peptide (VIP) with a multifaceted mode of action for respiratory indications, which is in Phase 3 clinical trials for treating COVID-19-induced acute respiratory distress syndrome and moderate to severe COVID-19 lung injury; in Phase 1 clinical trial for the treatment of patients with acute lung injury in other intensive care unit; and in Phase 2 clinical trial for the treatment of pulmonary sarcoidosis. The company is also developing ACER-001, a proprietary powder formulation of sodium phenylbutyrate, which has completed Phase 3 clinical trial for urea cycle disorders; and in Phase 1 clinical trial for the treatment of maple syrup urine disease. In addition, it is developing APR-TD011, a spray-formulated hypotonic acid-oxidizing solution, which is in Phase 2 clinical trial for treating epidermolysis bullosa. The company was founded in 2013 and is based in Geneva, Switzerland.

RhyGaze AG is pioneering a transformative approach with cone optogenetics, which has the potential to revolutionize vision restoration for patients suffering from blindness.

Ridgeline Discovery, a Versant Ventures Discovery Engine, creates and operates Versant-financed innovative biotech companies in partnership with entrepreneurs, industry and leading academics across Europe. In recent years, Ridgeline has assembled an international team of >50 highly experienced drug discovery professionals and built and operated several new successful companies, including Black Diamond Therapeutics (NASDAQ: BDTX), Bright Peak Therapeutics and Monte Rosa Therapeutics (NASDAQ: GLUE). Ridgeline is currently expanding its capabilities in Basel to support further company creation efforts in small molecules, biologics, and gene/cell therapy with focus on oncology and immunology.

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry ten years in a row by the Dow Jones Sustainability Indices (DJSI). For more information, please visit https://careers.roche.com Read our community guidelines here: https://www.roche.com/some-guidelines.htm #Roche #Biotechnology #Pharmaceuticals #Diagnostics #Healthcare #PersonalisedHealthcare #GreatPlaceToWork #Innovation

With the effective control of infectious diseases in many parts of the world, chronic, often non-communicable diseases have become the single largest cause of death and disability.Treatment of such chronic diseases is expensive and often ineffective. There is therefore a major need for novel treatment modalities to prevent rather than treat chronic diseases and that are available at affordable costs.Inducing long-lived antibody responses by vaccination against endogenous molecules, which are normally targeted by monoclonal antibodies, represents a promising way to tackle this issue.Saiba GmbH uses virally shaped nanoparticles as a scaffold for the generation of tailor-made vaccines. The nanoparticle base of the vaccines tricks the immune system into believing to be under viral attack, causing a strong immune response against the displayed antigen.

Sandoz is the global leader in generic and biosimilar medicines. ​ ​Our Purpose is to pioneer access to medicines for patients globally. We are on a mission to drive innovation in the healthcare industry by freeing up resources sustainably and responsibly while continuing to address global health challenges such as antimicrobial resistance.​ We are present in more than 100 countries and our medicines serve some 500 million people every year. We have two main global businesses: Generics - divided between standard generics and complex generics - and Biosimilars.

Somagenetix is a new company that aims at becoming a leading gene therapy company with first-in-class treatment for phagocyte-related disorders. We are spin-off from the University of Zurich and we are leveraging world-class scientific and clinical expertise to solve unmet medical needs through gene therapy. Carried by a highly experienced scientific team with over 17 years experience in gene therapy research, clinical development and applications, our mission is to cure all patients with Phagocyte Disorders. A cutting-edge technology with a complete & unique platform solving all challenges of ex-vivo gene therapies: specificity, long-term efficacy and safety. Our goal is to cure patients with immunodeficiency, neurodegeneration and cancer with brain metastasis via genetically enhanced phagocytes.

Spexis AG (SIX:SPEX) is a publicly-listed Swiss clinical-stage biopharmaceutical company developing rare disease and oncology treatments in indications where new therapeutic options are urgently needed. Spexis AG was launched in December 2021 by the reverse merger of EnBiotix, Inc. (Boston, MA, USA) and Polyphor AG (Allschwil, Switzerland), with EnBiotix shareholders resulting in the majority. Our focus is on chronic respiratory diseases (CRD), and our lead product candidate ColiFin® is P3 ready. ColiFin® is an inhaled colistimethate sodium product in-licensed from PARI Pharma GmbH for ex-European rights. Approved and marketed in Europe as a front-line therapy in cystic fibrosis (“CF”) patients, ColiFin® already has a proven safety, efficacy, and commercial track record. In the U.S., ColiFin® has Orphan Drug and Qualified Infectious Disease Product (“QIDP”) designations, which together will provide a total of 12 years of market exclusivity from NDA approval. We also have a “Study May Proceed” letter from the FDA regarding a single phase 3 study evaluating ColiFin® in CF patients being sufficient to support a future New Drug Application (“NDA”). The trial design has been endorsed by the Cystic Fibrosis Foundation (CFF) Therapeutic Development Network (TDN), the clinical development arm of the CFF. Of note, the CFF also invested in the pre-merger financing launching Spexis.

STALICLA SA is a Swiss clinical-stage biopharmaceutical company pioneering Neuro Precision Medicine in neurodevelopmental and neuropsychiatric disorders. With state-of-the-art technology platforms and clinical trials for Autism Spectrum Disorder (ASD) and Substance Use Disorder (SUD), STALICLA is changing the landscape of brain disease treatments. Neurodevelopmental Disorders: To propel neurodevelopmental research, STALICLA have identified patient subgroups and their matching candidate drugs within Autism Spectrum Disorder using its trailblazing, multi-omics DEPI platform. STALICLA is currently preparing Phase 2 trials for STP1, STALICLA's first patient subgroup-matched precision treatment. Substance Use Disorder research: STALICLA is working in partnership with the National Institute of Drug Abuse (NIDA) to advance Phase 3 clinical trials for the most clinically advanced drug candidate for cocaine abuse disorder, STP7. STALICLA is now raising series C funding to advance both verticals. For more information visit: https://stalicla.com.

Timeline (parent company Amazentis) is a Swiss longevity biotech positioned at the intersection of the consumer health, nutrition, and beauty sectors. With more than a decade of expertise in aging science research, Timeline seeks to push the boundaries of human healthspan, contributing to a future where everyone can live longer, healthier lives. The company is backed by over 15 years of research by distinguished scientists, multiple clinical studies, and over 50 patents. Nestlé Health Science and L'Oréal are investors in the company.

Translation-X is a spin-off project at the Biozentrum, University of Basel. We are developing novel pharmacological tools to reduce core symptoms of autism by targeting RNA translational machinery.

Leading with purpose. Every day. “Ultragenyx was founded to advance innovative medicines for rare and ultrarare diseases that have never been treated before. We are delivering transformative therapies across multiple indications, and we have one of the most robust and diverse clinical pipelines in rare disease. Our focus is on doing the right things for patients both during development and commercialization to deliver on the promise of these therapies in a way that's meaningful for rare disease communities.” Emil D. Kakkis, M.D., Ph.D. Chief Executive Officer and President We have an inclusive culture of value and respect. Ultragenyx brings novel products to those living with rare and ultrarare diseases with a focus on debilitating genetic diseases. Founded in 2010, we have rapidly built a diverse portfolio of approved therapies and products aimed at diseases with a high unmet medical need for which many have no approved therapies. It takes courage, care, talent, and dedication to make a meaningful impact for those living with rare diseases, their families and the rare disease community. We put our people first, so they can take care of the rare disease community. We purposefully cultivate and nurture a dynamic, supportive work environment where we encourage every team member to share their new ideas and help us unlock more possibilities. Our team is made up of exceptional and diverse people with a strong passion and commitment to helping those living with rare diseases. By embracing generosity, curiosity, inclusion, and humility we are constantly learning together—fostering an environment that supports profound growth and fulfillment. If you want to have a meaningful impact, do the best work of your career while having fun and growing professionally and personally, come join our team! Visit our community guidelines at: https://ultragenyx.co/community

Vandria is a biopharmaceutical company at the vanguard of mitochondrial research. They develop best-in-class small molecule mitophagy inducers to treat age-related and chronic diseases. Vandria is also developing mitophagy-inducing small molecules to address muscle, lung, and liver diseases, as well as a separate program targeting ferroptosis, a form of cell death.

VAXIMM is a privately held, Swiss/German biotech company that is developing oral T-cell immunotherapies for patients suffering from cancer. VAXIMM’s product platform is based on a live attenuated, safe, orally available bacterial vaccine strain, which is modified to stimulate patients’ cytotoxic T-cells to target specific structures of the tumor. The Company has a pipeline of complementary development candidates targeting different tumor structures. Lead product candidate, oral VXM01, activates killer cells targeting tumor-specific vasculature and certain immune-suppressive cells, thereby increasing immune cell infiltration in solid tumors. VXM01 is currently in clinical development for several tumor types, including brain cancer. VAXIMM has completed a clinical trial evaluating VXM01 in combination with the human anti-PD-L1 antibody, avelumab, as part of a scientific collaboration with Merck KGaA, Darmstadt, Germany. VAXIMM also has a collaboration agreement with China Medical System Holdings (CMS), granting CMS full rights in China and other Asian countries (excluding Japan) to VAXIMM’s existing programs. VAXIMM AG is headquartered in Basel, Switzerland. Its wholly owned subsidiary, VAXIMM GmbH, located in Mannheim, Germany, is responsible for the Company’s development activities.

Versameb AG is a privately held biotechnology company focusing on discovering and developing innovative RNA-based drugs for modulation of protein expression, including the ability to simultaneously influence several therapeutic targets, in a controlled manner, with one molecular construct, and cellular targeting. Based in Basel and fully operational from 2018, the company is led by an experienced scientific and leadership team with proven expertise in drug discovery and development from lab bench to patient. Versameb’s proprietary technology platform, VERSagile, optimizes the application of functional RNA in different disease contexts – making RNA druggable in new therapeutic areas others have been unable to solve. The pipeline includes lead candidate programs in Stress Urinary Incontinence (SUI) and solid tumors. Versameb is working towards the completion of a first in-human/proof-of-concept clinical study while advancing its platform.

Vifor Pharma is a Switzerland-based pharmaceutical company that develops nephrology and cardio-renal therapies for the treatment of heart failure and kidney diseases.

Virometix is a privately held Swiss biotechnology company developing a new generation of vaccines and immunotherapeutic drugs for the prevention and treatment of infectious and oncology diseases

Volumina Medical is a multi-award-winning start-up active in the field of medical devices supported by a solid network of investors. The company develops breakthrough innovations for plastic and reconstructive surgery. The first product is an implantable polymeric biomaterial and targets the regeneration of soft tissue of the human body which are damaged after tumor excision, genetic malformation or trauma.

Windward Bio is a clinical-stage, drug development company committed to improving outcomes for people living with advanced immunological diseases with an initial focus on severe respiratory conditions. The company is led by a highly experienced team of biopharmaceutical executives with deep discovery, development, and commercialization expertise. The company is advancing a potential best-in-class thymic stromal lymphopoietin (TSLP) monoclonal antibody into phase 2 development and creating novel, long-acting bispecific programs for immunological diseases.

Xeltis is developing artificial vessels and valves that are gradually replaced by patients’ own living healthy tissue. www.xeltis.com

Ymmunobio is a preclinical stage oncology biotech company focused on the development of innovative treatments for cancer patients through new classes of antibodies. Those treatments present a large market potential and broad applicability in solid tumors. Ymmunobio is making extensive progress in developing antibodies that have an influence on the immune system by reinstating its immune response to cancers or directly inhibiting cancer cell proliferation.